These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 4736493
1. Levodopa and dopamine in cerebrospinal fluid. Papavasiliou PS, Cotzias GC, Lawrence WH. Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493 [No Abstract] [Full Text] [Related]
2. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions. Mars H. Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061 [No Abstract] [Full Text] [Related]
4. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid]. Tohgi H, Ogawa M. No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277 [No Abstract] [Full Text] [Related]
5. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease. Mars H. Trans Am Neurol Assoc; 1973 Feb; 98():241-5. PubMed ID: 4784941 [No Abstract] [Full Text] [Related]
6. Ro 4-4602 and levodopa in the treatment of Parkinsonism. Miller EM, Wiener L. Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107 [No Abstract] [Full Text] [Related]
7. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration. Johnson RD, Ruthven CR, Goodwin BL, Sandler M. J Neural Transm; 1976 May; 38(3-4):181-91. PubMed ID: 956809 [Abstract] [Full Text] [Related]
8. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Fahn S. Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104 [No Abstract] [Full Text] [Related]
10. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. Marsden CD, Barry PE, Parkes JD, Zilkha KJ. J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682 [Abstract] [Full Text] [Related]
11. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease. Muenter MD, Dinapoli RP, Sharpless NS, Tyce GM. Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387 [No Abstract] [Full Text] [Related]
12. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa). Sharpless NS, Ericsson AD, McCann DS. Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098 [No Abstract] [Full Text] [Related]
13. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. Rinne UK, Sonninen V, Siirtola T. Eur Neurol; 1973 May; 9(6):349-62. PubMed ID: 4712542 [No Abstract] [Full Text] [Related]
14. MK 486 and levodopa in treatment of Parkinsonism. Lieberman AN, Derby BM, Feigenson J, Goodgold A, Nesbitte J, Resurreccion EC, Valdivia F. Dis Nerv Syst; 1973 May; 34(4):167-71. PubMed ID: 4711885 [No Abstract] [Full Text] [Related]
15. [Attempt at treating parkinsonism with L-dopa and Artane]. Stelmasiak Z, Lackowska H, Maksymowicz B. Pol Tyg Lek; 1971 Aug 23; 26(34):1325-6. PubMed ID: 5110789 [No Abstract] [Full Text] [Related]
16. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease. Ebinger G, Adriaenssens K. Clin Chim Acta; 1973 Nov 15; 48(4):427-31. PubMed ID: 4761590 [No Abstract] [Full Text] [Related]
20. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa. Stewart RM, Miller S, Gunder M. Acta Derm Venereol; 1983 Oct 15; 63(2):97-101. PubMed ID: 6189350 [Abstract] [Full Text] [Related] Page: [Next] [New Search]